Axxam and PerkinElmer Sign Exclusive Licensing Agreement for Photina® Technology
News May 23, 2007
Axxam retains the rights to use the technology for its discovery services to third parties, as assay development, high-throughput screening (HTS) and compound profiling, as well as for any further application of development of this technology. This agreement does not affect current discovery service contracts.
The terms of the agreement also provide for a formal research and development program between Axxam and PerkinElmer to develop additional Photina® GPCR and ion channel cell lines for use in high throughput screening and compound profiling
The Photina® technology is a luminescent cell-based assay platform optimized for screening important drug discovery targets, including G-protein coupled receptors (GPCRs) and ion channels.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019